The company is expecting $14.3 million in Q2 revenues, a 157 percent increase over the same quarter last year.
The acquisitions will enable Invitae to add reproductive health genetic testing to its portfolio and become what it calls a "comprehensive genomic information company."
The Broad's David Scott and Feng Zhang said whole-genome sequencing could be used to guide RNA selection for individuals undergoing genomic editing therapy.
The open-source MultiQC software platform aggregates multiple bioinformatics analyses into a single report for the purpose of quality control.
The Multiple Myeloma Research Foundation launched the MMRF Answer Fund to engage researchers, clinicians, and patients in the search for better treatments.
The group has filed a patent on the method and is interested in teaming up with an industry partner to commercialize it.
A pair of new studies evaluated whole-exome sequencing and other genetic tests in children with epilepsy and in other undiagnosed monogenic disease cases.
The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.
The new version of the mass spectrometry-based system adds 144 microbial species to its database and includes new tools for sample preparation.
The company's new QuantStudio 5 Dx Real-Time PCR system allows users to wield multi-modal software to detect pathogens.
The law firm alleges that the company misled investors about its progress in obtaining Medicare reimbursement for its cancer genomic tests.
The program, called Genetic Testing Solution, went into effect July 1 among Anthem Blue Cross' fully-insured and self-insured members.
Last week, GenomeWeb's readers were most interested in reports that Illumina has settled one patent infringement lawsuit with Qiagen over NGS technology.
IDbyDNA and ARUP Labs will offer their first test for pneumonia through ARUP's established clinical network in the coming weeks.
The gift will support work being done by Atul Butte using publicly availably health data to gain new insights on disease.
The services will couple NEB's reagents and expertise in enzyme development and manufacturing with TTP's Desktop Biology product development and engineering know-how.
Parent firm Gene by Gene calls the law "brief and vague" and is pushing for ancestry testing to be exempt from the provision of the genetic privacy statute.
The RightMed test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.
With new gene sequencing panels, investigators made firm or possible diagnoses in almost one-third of undiagnosed autoinflammation and vasculitis cases.